Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tritanrix-HepB low thio · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | - |
| Group B | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Tritanrix™-HepB low thio / | BIOLOGICAL | One dose as intramuscular injection at 6, 10 and 14 weeks of age. |
| Hib 2.5 | BIOLOGICAL | One dose as intramuscular injection at 6, 10 and 14 weeks of age. |
| Tritanrix™-HepB | BIOLOGICAL | One dose as intramuscular injection at 6, 10 and 14 weeks of age. |
| Hiberix™ | BIOLOGICAL | One dose as intramuscular injection at 6, 10 and 14 weeks of age. |
| Unconjugated Hib vaccine (plain PRP) | BIOLOGICAL | One dose as intramuscular injection at 10 months of age |
Inclusion Criteria: * Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study. * A male or female between, and including, 6 and 8 weeks of age at the time of the first vaccination. * Written inform...
Tritanrix-HepB low thio is an investigational vaccine being studied for the prevention of Haemophilus Influenzae Type b disease. It is a combination vaccine that includes a low thimerosal formulation. The drug is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
Tritanrix-HepB low thio is developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the vaccine's safety and immunogenicity in pediatric populations.
Tritanrix-HepB low thio is in Phase 2 clinical development. It is an investigational vaccine, meaning it has not been approved for commercial use. The Phase 2 trial has been completed, and the results will inform whether further clinical studies are warranted.
Tritanrix-HepB low thio has one completed Phase 2 clinical trial registered as NCT01061541. This study evaluated the immunogenicity, safety, and reactogenicity of the vaccine compared to another GSK vaccine in 192 healthy infants aged 6 weeks and older in the Philippines.
Tritanrix-HepB low thio is a monoclonal antibody vaccine designed to elicit an immune response against Haemophilus Influenzae Type b. By presenting antigens to the immune system, it aims to stimulate the production of protective antibodies that can prevent infection.